Mixed Findings on Renal Outcomes With DPP-4 Inhibitors in T2D Mixed Findings on Renal Outcomes With DPP-4 Inhibitors in T2D
Renal outcomes data from two large cardiovascular-outcomes trials with the type 2 diabetes drugs saxagliptin and sitagliptin, both DPP-4 inhibitors, hint at some kidney benefit with saxagliptin.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Januvia | Urology & Nephrology